Take the assessment
45-min intake with your dedicated health coach. A free health-score quiz is available before the paid intake.
EzetimibeEzetimibe
Selective cholesterol absorption inhibitor blocking NPC1L1 transporter. Provides additive 15 to 25% LDL reduction on top of statin. IMPROVE-IT demonstrated cardiovascular event reduction.
HSA/FSA eligible · No commitmentHSA/FSA eligible · No commitment
Ezetimibe
Marketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
How it works
From sign-up to treatment.From sign-up to your first dose.
Get your labs drawn
Complete lab panel ordered by your provider, drawn at any of 4,000 partnered lab locations nationwide. Results typically return within 14 days.
Provider reviews your results
A licensed medical provider reviews your labs and history to evaluate whether Ezetimibe is appropriate for you. Eligibility and any prescription are determined at the provider's discretion.
If eligible, treatment ships to your door
If your provider prescribes Ezetimibe, it ships from a licensed pharmacy. Your coach supports you through follow-up labs and ongoing monitoring.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
The science
How Ezetimibe works.
Inhibits NPC1L1 cholesterol transporter on intestinal enterocytes, blocking dietary and biliary cholesterol absorption. Reduced hepatic cholesterol delivery upregulates LDL receptors via SREBP-2.
Hypercholesterolemia (adjunct to statin)Statin-intolerant patients (monotherapy)Familial hypercholesterolemiaSitosterolemia
Eligibility, dosing, and outcomes vary. Any prescription is at the discretion of a partnered licensed medical provider based on your labs and medical history.
Clinical evidence
The research behind Ezetimibe.
IMPROVE-IT: Ezetimibe Added to Statin After ACS
New England Journal of Medicine (2015)
Reduced LDL to 53.7 vs 69.5 mg/dL and major CV events by 6.4% over 7 years in 18,144 ACS patients.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Diarrhea
- Abdominal pain
- Fatigue
- Myalgia (rare)
Less common but serious risks
- Hepatotoxicity (rare with statin combination)
Generally not appropriate for
- Active liver disease (with statin)
- Pregnancy
Typical monitoring
- Lipid panel
- Liver function (with statin)
- Muscle symptoms
FAQ
Quick answers.
Selective cholesterol absorption inhibitor blocking NPC1L1 transporter. Provides additive 15 to 25% LDL reduction on top of statin. IMPROVE-IT demonstrated cardiovascular event reduction.
Additional 15 to 25% LDL reduction on statin. IMPROVE-IT: 6.4% MACE reduction over 7 years. Well tolerated. Synergistic with statins.
Common side effects include: diarrhea, abdominal pain, fatigue, myalgia (rare). Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Selective cholesterol absorption inhibitor blocking NPC1L1 transporter. Provides additive 15 to 25% LDL reduction on top of statin. IMPROVE-IT demonstrated cardiovascular event reduction.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.